Planned $3.1B offering hitches BeiGene’s name to nascent STAR

Approval of BeiGene’s proposed $3.1 billion listing on Shanghai’s STAR board sets up the company to become the first biopharma listed in Shanghai, Hong Kong and New York, and lends the nascent board the halo of the company’s pathfinding reputation.

For BeiGene Ltd. (NASDAQ:BGNE; HKEX:6160), the financing comes as the biotech is growing its global footprint and expanding its roster of approved therapies...